Skip to main content

Table 5 Recurrent Copy Number Aberrations (CNA) in CD19+ B-cells. 143 CNA had been observed

From: Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification

Chr Cytoregion Recurrence Recurrence including mosaicism CN state Gene Minimal common size (kbp) Genic region: total (T)
Exonic (E)
Intronic (I)
CNA reported in DGV
1 p33 2 2 Loss FAF1 31 I No
1 p32.2 2 2 Gain C1orf168 50.2 E/I No
2 p23.2 2 2 Gain ALK 62 E/I Yes
2 q21.2–q21.3 2 2 Gain MGAT5 72 E/I No
3 p24.2 2 2 Gain THRB 55.7 I No
3 q11.2 2 3 Gain LOC255025 50 E/I No
3 q12.2 2 3 Gain ABI3BP 143 E/I Yes
3 q13.13 2 3 Gain DZIP3 10.6 I No
3 q13.31 2 3 Gain ZBTB20 39 I No
3 q13.31 2 3 Gain GAP43 399 T No
3 q13.31 2 3 Gain LSAMP 53 I No
3 q13.33 2 3 Gain TMEM39A 176 T No
3 q13.33 2 3 Gain KTELC1 176 T No
3 q13.33 2 3 Gain C3orf1 176 T No
3 q13.33 2 3 Gain CD80 176 T No
3 q13.33 2 3 Gain ADPRH 176 T No
3 q21.1 2 3 Gain HSPBAP1 101 E/I No
3 q21.1 2 4 Gain DIRC2 101 T No
3 q21.1 2 4 Gain LOC100129550 101 T Yes
3 q21.1 2 4 Gain SEC22A 114 T No
3 q21.1 2 4 Gain PTPLB 125 T No
3 q21.1 3 4 Gain MYLK 70 E/I No
3 q21.1 2 4 Gain CCDC14 121 E/I Yes
3 q21.2 2 4 Gain KALRN 169 T No
3 q21.2 2 4 Gain UMPS 169 T No
3 q21.2 2 4 Gain ZNF148 164 E/I Yes
3 q21.2 2 4 Gain ALDH1L1 171 E/I No
3 q21.3 3 4 Gain TXNRD3IT1 299 E/I No
3 q21.3 3 4 Gain CHCHD6 299 E/I No
3 q21.3 2 4 Gain KLHDC6 95 T No
3 q21.3 2 4 Gain RUVBL1 211 E/I Yes
3 q21.3 2 4 Gain EEFSEC 211 E/I Yes
3 q21.3 2 4 Gain GATA2 76 E/I Yes
3 q21.3 3 4 Gain LOC90246 76 T Yes
3 q21.3 2 4 Gain C3orf27 120.7 T Yes
3 q21.3 2 4 Gain TMCC1 268 T No
3 q21.3 2 4 Gain COL6A4P2 131 T Yes
3 q22.1 2 4 Gain MRPL3 62 E/I Yes
3 q22.1 2 4 Gain SNORA58 62 T Yes
3 q22.1 3 5 Gain CPNE4 46 I Yes
3 q22.1 2 4 Gain CPNE4 155 E/I Yes
3 q22.1 2 4 Gain TMEM108 120 I Yes
3 q22.1 2 4 Gain TOPBP1 69 E/I No
3 q22.1 2 4 Gain RYK 225 T No
3 q22.1 2 4 Gain ANAPC13 197 T Yes
3 q22.1 2 4 Gain CEP63 197 T Yes
3 q22.2 2 4 Gain EPHB1 144 E/I No
3 q22.2 2 4 Gain PPP2R3A 85 E/I No
3 q22.3 2 4 Gain SOX14 925 T No
3 q22.3 3 4 Gain CLDN18 121 T Yes
3 q22.3 2 4 Gain ARMC8 77 E/I Yes
3 q22.3 2 4 Gain TXNDC6 77 E/I Yes
3 q22.3 2 4 Gain ESYT3 202.7 E/I No
3 q22.3 2 4 Gain CEP70 202.7 T No
3 q22.3 2 4 Gain FAIM 202.7 T No
3 q22.3 2 4 Gain PIK3CB 202.7 E/I No
3 q22.3 3 4 Gain LOC729627 193 T No
3 q22.3 3 4 Gain LOC389151 193 T No
3 q22.3 3 4 Gain FLJ46210 193 T No
3 q22.3 3 4 Gain BPESC1 193 T No
3 q22.3 2 4 Gain PISRT1 319 T No
3 q23 2 4 Gain MRPS22 89 E/I No
3 q23 2 4 Gain COPB2 89 T No
3 q23 3 4 Gain NMNAT3 277.8 E/I No
3 q23 4 5 Gain CLSTN2 46 I Yes
3 q23 2 4 Gain TRIM42 443 T Yes
3 q23 2 4 Gain SLC25A36 443 T Yes
3 q24 2 4 Gain SLC9A9 138 E/I Yes
3 q24 2 4 Gain PLSCR4 47 E/I No
3 q24 2 4 Gain PLSCR5 69 T No
3 q24 2 4 Gain AGTR1 194 E/I No
3 q25.1 2 4 Gain P2RY13 74 E/I No
3 q25.1 2 4 Gain MED12L 74 E/I No
3 q25.1 2 4 Gain P2RY13 74 T No
3 q25.2 2 4 Gain SGEF 364 E/I Yes
3 q25.2–q25.31 3 4 Gain MME 87.4 E/I No
3 q25.32 2 4 Gain VEPH1 78 E/I Yes
3 q25.32 2 4 Gain C3orf55 78 E/I No
3 q25.32 3 4 Gain MLF1 50 E/I No
3 q26.1 2 4 Gain C3orf57 120.6 E/I No
3 q26.1 2 4 Gain OTOL1 120.6 T No
3 q26.1 3 4 Gain SI 747 T No
3 q26.1 3 4 Gain BCHE 329 E/I No
3 q26.1 2 4 Gain ZBBX 307 T No
3 q26.2 6 7 Gain MDS1 28 E/I No
3 q26.2 2 4 Gain TERC 59 T Yes
3 q26.2 2 4 Gain ARPM1 59 T Yes
3 q26.2 2 4 Gain MYNN 59 T Yes
3 q26.2 2 4 Gain LRRC34 59 E/I Yes
3 q26.2 3 5 Gain TNIK 31 E/I No
3 q26.31 2 4 Gain NLGN1 125 I Yes
3 q26.31 2 4 Gain NLGN1 64 E/I No
3 q26.31 2 4 Gain NAALADL2 113 E/I Yes
3 q26.32 2 4 Gain TBL1XR1 60 E/I No
3 q26.32 2 4 Gain KCNMB2 121 E/I No
3 q26.33 2 4 Gain USP13 59 E/I No
3 q26.33 2 4 Gain PEX5L 81 E/I No
3 q26.33 2 4 Gain CCDC39 118 E/I Yes
3 q27.1 2 4 Gain YEATS2 112 E/I No
3 q27.1 2 4 Gain MAP6D1 112 T No
3 q27.1 2 4 Gain PARL 112 E/I No
3 q27.2 2 4 Gain VPS8 218 E/I No
3 q27.2 2 4 Gain ETV5 157 T No
3 q27.2 2 4 Gain DGKG 157 E/I No
3 q27.3 2 4 Gain CRYGS 110 E/I No
3 q27.3 2 4 Gain TBCCD1 110 T No
3 q27.3 2 4 Gain DNAJB11 110 T No
3 q27.3 2 4 Gain AHSG 110 T Yes
3 q27.3 2 4 Gain FETUB 110 E/I Yes
3 q27.3 2 4 Gain ST6GAL1 46 E/I Yes
3 q27.3 2 4 Gain MASP1 428 E/I No
3 q27.3 3 4 Gain RTP4 148 T No
3 q27.3 2 4 Gain SST 428 T No
3 q27.3 2 4 Gain FLJ42393 191 T Yes
3 q28 3 4 Gain LPP 191 E/I Yes
3 q28 2 4 Gain TP63 142 E/I No
3 q28 2 4 Gain CLDN1 203 T No
3 q28 2 4 Gain CLDN16 203 T No
3 q28 2 4 Gain TMEM207 203 T No
3 q29 2 4 Gain C3orf59 396 E/I No
3 q29 2 4 Gain MGC2889 396 T Yes
3 q29 2 4 Gain HRASLS 396 T Yes
3 q29 2 4 Gain ATP13A5 396 E/I No
3 q29 2 4 Gain ATP13A4 158 E/I Yes
3 q29 2 4 Gain OPA1 158 T Yes
3 q29 2 4 Gain GP5 97 E/I No
3 q29 2 4 Gain ATP13A3 97 T Yes
3 q29 2 4 Gain TM4SF19 87 E/I Yes
3 q29 2 4 Gain UBXN7 87 E/I Yes
3 q29 2 4 Gain DLG1 240 E/I Yes
3 q29 2 4 Gain FYTTD1 50 T Yes
3 q29 2 4 Gain LRCH3 50 E/I Yes
3 q29 2 4 Gain RPL35A 91 E/I Yes
3 q29 2 4 Gain IQCG 91 E/I Yes
3 q29 2 4 Gain LMLN 91 T Yes
4 q13.3 2 2 Gain SLC4A4 46 E/I No
11 p15.1 2 2 Gain NELL1 43 I No
14 q13.1 2 2 Gain NPAS3 43 I Yes
16 p11.1 2 2 Gain LOC283914 277 T Yes
21 p11.2–p11.1 2 3 Loss TPTE 107 T Yes
X p22.33 3 3 Gain DHRSX 31 E/I Yes
X q12 2 2 Gain EDA2R 91 E/I Yes
Y q11.21 2 2 Gain USP9Y 60 E/I No
  1. 129 gains concerned the long arm of chromosome 3 (3q). 123 gains concerned gene coding regions. 75 CNA did not include previously reported polymorphism (Database of Genomic Variants, DGV). Gain of one exon of MDS1 (part of MECOM gene) was recurrently observed in 7 patients (including mosaicism phenomenon)
  2. Chr chromosome, Recurrence number of patients with the same CNA, CN state Copy Number state, gain or loss